RU2012148602A - METHOD FOR INTEGRATED EVALUATION OF INDICATIONS FOR PURPOSE OF CARDIOMETABOLIC THERAPY IN INFECTIOUS DISEASES - Google Patents
METHOD FOR INTEGRATED EVALUATION OF INDICATIONS FOR PURPOSE OF CARDIOMETABOLIC THERAPY IN INFECTIOUS DISEASES Download PDFInfo
- Publication number
- RU2012148602A RU2012148602A RU2012148602/14A RU2012148602A RU2012148602A RU 2012148602 A RU2012148602 A RU 2012148602A RU 2012148602/14 A RU2012148602/14 A RU 2012148602/14A RU 2012148602 A RU2012148602 A RU 2012148602A RU 2012148602 A RU2012148602 A RU 2012148602A
- Authority
- RU
- Russia
- Prior art keywords
- points
- point
- cardiometabolic
- indicators
- therapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 12
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract 7
- 208000035473 Communicable disease Diseases 0.000 title 1
- 238000011156 evaluation Methods 0.000 title 1
- 230000003205 diastolic effect Effects 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims abstract 3
- 208000015181 infectious disease Diseases 0.000 claims abstract 3
- 230000002458 infectious effect Effects 0.000 claims abstract 3
- 230000003902 lesion Effects 0.000 claims abstract 3
- 230000002107 myocardial effect Effects 0.000 claims abstract 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims abstract 2
- 108010082126 Alanine transaminase Proteins 0.000 claims abstract 2
- 102000004420 Creatine Kinase Human genes 0.000 claims abstract 2
- 108010042126 Creatine kinase Proteins 0.000 claims abstract 2
- 108090000790 Enzymes Proteins 0.000 claims abstract 2
- 102000004190 Enzymes Human genes 0.000 claims abstract 2
- 208000001871 Tachycardia Diseases 0.000 claims abstract 2
- 102000004903 Troponin Human genes 0.000 claims abstract 2
- 108090001027 Troponin Proteins 0.000 claims abstract 2
- 230000036471 bradycardia Effects 0.000 claims abstract 2
- 208000006218 bradycardia Diseases 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 238000007911 parenteral administration Methods 0.000 claims abstract 2
- 208000024891 symptom Diseases 0.000 claims abstract 2
- 230000006794 tachycardia Effects 0.000 claims abstract 2
- 108010050201 2-hydroxybutyrate dehydrogenase Proteins 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000035211 Heart Murmurs Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019842 Hepatomegaly Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 208000031353 Systolic Murmurs Diseases 0.000 claims 1
- 102000013394 Troponin I Human genes 0.000 claims 1
- 108010065729 Troponin I Proteins 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 206010007625 cardiogenic shock Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002336 repolarization Effects 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 102100034613 Annexin A2 Human genes 0.000 abstract 1
- 108090000668 Annexin A2 Proteins 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- 230000004872 arterial blood pressure Effects 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
1. Способ оценки показаний к кардиометаболической терапии при инфекционных поражениях миокарда у детей, заключающийся в выявлении и количественной оценке клинических, электрокардиографических, биохимических и эхокардиографических показателей, каждый из которых оценивают от 1 до 3 баллов, баллы суммируют и по полученному результату осуществляют оценку показания к кардиометаболической терапии, при общей сумме меньше 3 баллов кардиометаболическая терапия не показана, при общей сумме от 3 баллов до 7 баллов включительно назначают пероральное применение кардиометаболических препаратов, при общей сумме от 8 баллов и выше назначают парентеральное введение кардиометаболических препаратов.2. Способ по п.1, отличающийся тем, что в качестве клинических показателей оценивают аускультативную симптоматику: звучность тонов, наличие шумов; показатели артериального давления.3. Способ по п.1, отличающийся тем, что в качестве биохимических показателей оценивают активность кардиоспецифичных ферментов: МВ-фракции креатинфосфокиназы, α-гидрокисбутиратдегидрогеназы, аспарагиновой трансаминазы, аланиновой трансаминазы) и кардиоспецифичного белка тропонина I.4. Способ по п.1, отличающийся тем, что эхокардиографическое исследование осуществляют с применением допплерографии для оценки диастолической функции желудочков.5. Способ по п.1, отличающийся тем, что клинические, электрокардиографические, биохимические и эхокардиографические показатели оценивают в баллах, а именноприглушенность или глухость тонов - 1 балл,систолический и/или диастолический шум - 1 балл,тахикардия или брадикардия, не соответствующие фазе заболевания - 1. A method for assessing indications for cardiometabolic therapy for infectious myocardial lesions in children, which consists in identifying and quantifying clinical, electrocardiographic, biochemical and echocardiographic indicators, each of which is evaluated from 1 to 3 points, the scores are summarized and, according to the result, the indications for cardiometabolic therapy, with a total amount of less than 3 points, cardiometabolic therapy is not indicated, with a total amount of 3 points to 7 points inclusive, oral administration of cardiometabolic drugs is prescribed, with a total amount of 8 points or more, parenteral administration of cardiometabolic drugs is prescribed. The method according to claim 1, characterized in that auscultatory symptoms are evaluated as clinical indicators: sonority of tones, the presence of noise; indicators of arterial pressure.3. The method according to claim 1, characterized in that the activity of cardiospecific enzymes is evaluated as biochemical indicators: MB-fraction of creatine phosphokinase, α-hydrokisbutyrate dehydrogenase, aspartic transaminase, alanine transaminase) and cardiospecific troponin protein I.4. The method according to claim 1, characterized in that the echocardiographic study is carried out using Doppler ultrasound to assess the diastolic function of the ventricles. The method according to claim 1, characterized in that clinical, electrocardiographic, biochemical and echocardiographic indicators are evaluated in points, namely, muffled or dull tones - 1 point, systolic and / or diastolic noise - 1 point, tachycardia or bradycardia that do not correspond to the phase of the disease -
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012148602/14A RU2539990C2 (en) | 2012-11-15 | 2012-11-15 | Method of complex evaluation of indications for administration of cardiometabolic therapy in case of infectious diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012148602/14A RU2539990C2 (en) | 2012-11-15 | 2012-11-15 | Method of complex evaluation of indications for administration of cardiometabolic therapy in case of infectious diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012148602A true RU2012148602A (en) | 2014-05-20 |
| RU2539990C2 RU2539990C2 (en) | 2015-01-27 |
Family
ID=50695632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012148602/14A RU2539990C2 (en) | 2012-11-15 | 2012-11-15 | Method of complex evaluation of indications for administration of cardiometabolic therapy in case of infectious diseases |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2539990C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2714178C2 (en) * | 2017-09-27 | 2020-02-12 | Татьяна Александровна Руженцова | Method for assessing risk of adverse outcomes of infectious myocardial injuries in children and adolescents |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10507009B2 (en) | 2017-10-05 | 2019-12-17 | EchoNous, Inc. | System and method for fusing ultrasound with additional signals |
| WO2020076627A1 (en) | 2018-10-08 | 2020-04-16 | EchoNous, Inc. | Device including ultrasound, auscultation, and ambient noise sensors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181564C2 (en) * | 1998-12-15 | 2002-04-27 | Новокузнецкий государственный институт усовершенствования врачей | Method for making metabolism correction within the framework of intensive care complex for treating hypovolemic shock |
| UA67227U (en) * | 2011-07-05 | 2012-02-10 | Алексей Маркович Давиденко | method for prognostication of the course of acute infectious myocarditis in children |
-
2012
- 2012-11-15 RU RU2012148602/14A patent/RU2539990C2/en active IP Right Revival
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2714178C2 (en) * | 2017-09-27 | 2020-02-12 | Татьяна Александровна Руженцова | Method for assessing risk of adverse outcomes of infectious myocardial injuries in children and adolescents |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2539990C2 (en) | 2015-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corrado et al. | Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria | |
| Palatini et al. | Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension | |
| Calò et al. | Echocardiographic findings in 2261 peri-pubertal athletes with or without inverted T waves at electrocardiogram | |
| O’Driscoll et al. | Cardiac autonomic and left ventricular mechanics following high intensity interval training: a randomized crossover controlled study | |
| Lv et al. | Epidemiology and diagnosis of viral myocarditis | |
| RU2012148602A (en) | METHOD FOR INTEGRATED EVALUATION OF INDICATIONS FOR PURPOSE OF CARDIOMETABOLIC THERAPY IN INFECTIOUS DISEASES | |
| Okoye et al. | Electrocardiographic abnormalities in treatment-naïve HIV subjects in south-east Nigeria | |
| Tadic et al. | The association between heart rate variability and biatrial phasic function in arterial hypertension | |
| O’Neill et al. | Clinical, electrophysiological and imaging predictors of atrial fibrillation ablation outcome | |
| Demir et al. | Effect of hepatitis C virus infection on the right ventricular functions, pulmonary arterypressure and pulmonary vascular resistance | |
| Tsiberkin et al. | Hypokalemia in hospitalized patients with pneumonia associated with COVID-19 | |
| Morka et al. | Left ventricular diastolic dysfunction assessed by conventional echocardiography and spectral tissue doppler imaging in adolescents with arterial hypertension | |
| Speranza et al. | Adult ECG criteria for left ventricular hypertrophy in young competitive athletes | |
| Chen et al. | e0613 Plasma microRNA-361-5p as a biomarker of chronic heart failure | |
| Harada et al. | Rubella-associated perimyocarditis: A case report | |
| Akasheva et al. | HEART AND AGE (PART II): CLINICAL MANIFESTATIONS OF AGEING | |
| de Gregorio et al. | Solitary papillary muscle hypertrophy in young athletes: a rationale for inverted T-waves on ECG? | |
| Kumar et al. | Atypical presentations in dengue viral infection: experiences at a tertiary care centre in north India | |
| Hsiao | Left atrial expansion index is associated with recurrent stroke | |
| Gorshunova et al. | ASSOCIATION OF HYPERTENSIVE ENDOTHELIAL DYSFUNCTION WITH THE SEVERITY OF MYOCARDIAL DYSFUNCTION AND CHRONIC HEART FAILURE IN ELDERLY PATIENTS | |
| RH Allam et al. | Cardiovascular effects of oral antiviral treatment for non-cardiac HCV patients | |
| Mahishale et al. | Cardiovascular profile of patients with chronic kidney disease | |
| Minopoli et al. | Arrhythmogenic Cardiomyopathy or “Athlete’s Heart”? A Systematic Approach to Differential Diagnosis | |
| Goudot et al. | P731 Carotid elastic properties impairment in case of Bicuspid aortic valve: myth or reality? | |
| Heusinkveld et al. | Augmentation index acts as ventricular-arterial coupling parameter but not as proxy for wave reflection magnitude |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151116 |
|
| NF4A | Reinstatement of patent |
Effective date: 20170321 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181116 |
|
| NF4A | Reinstatement of patent |
Effective date: 20200217 |
|
| HE4A | Change of address of a patent owner |
Effective date: 20200824 |